AMS-17

CAT: 0804-HY-146765-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-146765-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders, such as vascular dementia (VaD) [1][2].
CAS Number
[3019885-78-7]
UNSPSC
12352005
Target
NOD-like Receptor (NLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ams-17.html
Purity
98.09
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1N(CCCN1S(=O)(C2=CC=C(C=C2)C(F)(F)F)=O)C3=CN=CN=C3
Molecular Formula
C15H13F3N4O3S
Molecular Weight
386.35
References & Citations
[1]Zhang C, et al. Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation. Bioorg Med Chem.|[2]Akif A, et al. Targeting NLRP3 signaling with a novel sulfonylurea compound for the treatment of vascular cognitive impairment and dementia. Fluids Barriers CNS. 2025 Jun 3;22 (1) :55.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NLRP3

Popular Products